Y-mAbs Therapeutics, Inc. - Common Stock, $0.0001 par value per share (YMAB)

Historical Holders from Q3 2018 to Q3 2025

Symbol
YMAB
Type / Class
Equity / Common Stock, $0.0001 par value per share
Shares outstanding
45.1M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
16.4K
Holdings value
$78.3K
% of all portfolios
0%
Grand Portfolio weight change
0%
Number of holders
2
Number of buys
1
Number of sells
-94
Average Value change %
0%
Average buys %
+0%
Average sells %
-0.002%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Y-mAbs Therapeutics, Inc. - Common Stock, $0.0001 par value per share (YMAB)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ACORN BIOVENTURES, L.P. 6.2% -11.4% $13.3M -$1.43M 2.8M -9.69% Anders Hove 19 Aug 2025

Institutional Holders of Y-mAbs Therapeutics, Inc. - Common Stock, $0.0001 par value per share (YMAB)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 16.4K $78.3K -$125M $6.66 2
2025 Q2 27.9M $126M -$3.99M $4.51 96
2025 Q1 28.8M $128M -$6.93M $4.43 102
2024 Q4 28.8M $225M -$943K $7.83 111
2024 Q3 25.7M $339M +$17.3M $13.15 105
2024 Q2 24.3M $294M +$14.8M $12.08 95
2024 Q1 23M $374M +$49.1M $16.26 94
2023 Q4 20.2M $138M +$5.16M $6.82 93
2023 Q3 19.7M $107M +$812K $5.45 98
2023 Q2 19.5M $132M +$4.78M $6.79 94
2023 Q1 19M $95.4M -$1.13M $5.01 84
2022 Q4 19.3M $94.4M -$55.2M $4.88 90
2022 Q3 23.6M $340M -$17.9M $14.42 95
2022 Q2 24.8M $375M -$7.58M $15.13 90
2022 Q1 25.3M $301M -$14.9M $11.88 87
2021 Q4 25.7M $417M -$24.2M $16.21 94
2021 Q3 26.2M $749M -$2.98M $28.54 96
2021 Q2 26.1M $887M -$1.16M $33.80 99
2021 Q1 26.3M $796M +$116M $30.24 116
2020 Q4 22.8M $1.13B +$38.4M $49.51 115
2020 Q3 21.4M $823M +$3.02M $38.39 105
2020 Q2 21.3M $920M +$53.4M $43.20 108
2020 Q1 20.1M $522M +$16M $26.10 80
2019 Q4 19.4M $606M +$185M $31.25 81
2019 Q3 13.1M $342M +$56.5M $26.06 65
2019 Q2 11M $251M +$54.3M $22.87 59
2019 Q1 8.48M $222M -$3.12M $26.21 44
2018 Q4 8.69M $176M +$16.9M $20.34 42
2018 Q3 7.73M $205M +$205M $26.56 38